Tempus Unveils Fuses Program for Innovative Therapeutic Research

Tempus has unveiled its Fuses program aimed at revolutionizing therapeutic research and establishing a cutting-edge diagnostic platform using its innovative foundation model. The program, driven by Tempus AI, Inc., focuses on leveraging the company’s exclusive dataset to extract valuable insights beneficial for both patient care and research. By merging the potency of its data with machine learning capabilities, Tempus aims to create an AI-enabled diagnostic platform that provides physicians with an extensive array of algorithmic tests tailored to bring precision medicine into a realm of reality.

Over the span of the last ten years, Tempus has meticulously curated a diverse data library, encompassing over 40 million research records. Within this repository, more than 1.5 million records are intricately connected with clinical data that is directly correlated with genomic details. Additionally, the archive includes 2 million entries with imaging data and roughly 300,000 records containing both genomic and whole transcriptomic information. This vast and intricate dataset equips the company to unearth groundbreaking discoveries previously considered unattainable.

Fuses is set to expedite Tempus’ expansive testing portfolio, broadening its collection of AI-driven diagnostics. The program’s objective is to transform the insights derived from Fuses into clinically substantiated algorithmic diagnostics that have the potential to enable highly personalized care. For instance, these diagnostics might aid in identifying patients who are unlikely to respond to approved treatments or those susceptible to severe treatment-related complications. Tempus has initiated this endeavor with the introduction of the Immune Profile Score (IPS) the previous year, a versatile biomarker serving as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy.

Eric Lefkofsky, the Founder and CEO of Tempus, articulated, “We have dedicated the past decade to constructing, expanding, and refining one of the most comprehensive datasets in our sector. Presently, we are on the verge of crafting the world’s most extensive diagnostic model, tailored to address critical, unresolved inquiries and enhance the intelligence and personalization of our diagnostics. We are at the brink of delivering tangible, transformative change in aligning the right therapies with the right patients – thereby actualizing personalized care for millions.”

The foundational principle underpinning Fuses revolves around acquiring generalizable rules that discern prognosis and drug efficacy in real-world medical practice. In its pursuit to deepen researchers’ comprehension of the causes behind unsuccessful clinical trials, determine new applications for experimental drugs, optimize trial structures, and uncover combination therapies to heighten patient outcomes, the model aspires to reveal biomarker regulations. It might also uncover mechanisms of drug responses and resistances, potentially catalyzing the emergence of a new wave of companion diagnostics and therapeutic investigations.

In conclusion, Tempus strives to propel precision medicine through the pragmatic application of artificial intelligence in the healthcare domain. By offering AI-powered precision medicine solutions entrenched in one of the planet’s extensive multimodal data banks, Tempus seeks to furnish physicians with the necessary tools to provide customized patient care. Simultaneously, the company aims to expedite the discovery, development, and delivery of optimal therapeutics, ensuring that every patient benefits from the treatment insights gleaned from preceding experiences. Through its state-of-the-art technologies and relentless pursuit of innovation, Tempus remains dedicated to forging a future where personalized medicine is the standard of care.